Journal
DRUGS
Volume 81, Issue 10, Pages 1229-1233Publisher
ADIS INT LTD
DOI: 10.1007/s40265-021-01550-w
Keywords
-
Categories
Ask authors/readers for more resources
Loncastuximab tesirine is an antibody-drug conjugate developed for the treatment of B cell lymphomas, currently approved in the US for specific types of lymphoma treatment while being researched for treatments of other types of lymphoma.
Loncastuximab tesirine (loncastuximab tesirine-lpyl; ZYNLONTA (TM)) is an antibody-drug conjugate being developed for the treatment of B cell lymphomas by ADC Therapeutics SA. Loncastuximab tesirine consists of a pyrrolobenzodiazepine DNA-alkylating warhead covalently attached via a cleavable linker to an anti-CD19 antibody that binds to B cells. It is currently approved in the US for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL), and is being developed for the treatment of mantle-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. This article summarizes the milestones in the development of loncastuximab tesirine leading to this first approval for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (NOS), DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available